PROTAC AR Degrader-4 is primarily used in research focused on targeted protein degradation, specifically for the androgen receptor (AR). This compound is designed to address conditions like prostate cancer, where AR signaling plays a critical role in disease progression. By leveraging the PROTAC (Proteolysis Targeting Chimera) technology, it facilitates the degradation of AR proteins, thereby inhibiting their function and reducing cancer cell growth. Its application is particularly valuable in studying resistance mechanisms in AR-driven cancers and exploring novel therapeutic strategies. Researchers also utilize it to understand the broader implications of targeted protein degradation in oncology and other diseases involving aberrant protein activity.